 NEW YORK, Oct. 04, 2021 GLOBE NEWSWIRE -- IN8bio, Inc. Nasdaq: INAB, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced that William Ho, Chief Executive Officer and co-founder of IN8bio, will present a company overview as well as participate on an Oncology panel at BioFuture 2021. Kate Rochlin, Vice President, Operations and Innovation of IN8bio, will present on the companys gamma delta T-cell programs in Oncology at the Advanced Therapies Congress Expo 2021. 